Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Jayasree K. Iyer and Marijn Verhoef to present AMR Benchmark findings in Basel

On March 7, Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, and Marijn Verhoef, Company Engagement Manager, will meet with the Manufacturing Work Group of the AMR Industry Alliance in Basel to discuss how pharmaceutical companies are addressing the rise of drug resistance. The goal of the meeting is to bring together key stakeholders from the industry to exchange information about pharmaceutical company action on AMR, the expectations and opportunities to make change and curb drug resistance.

Date

07 March 2018

Jayasree and Marijn will present the key findings of the Antimicrobial Resistance Benchmark  with a focus on antibiotic manufacturing and environmental risk-management strategies for slowing AMR. The AMR Benchmark includes detailed analyses of companies’ performances in three areas of corporate activity: R&D for new antimicrobials, policies for ensuring responsible antibiotic manufacturing, and approaches to ensuring antimicrobials are accessible and being used wisely. It aims to guide and incentivise pharmaceutical companies to adopt and implement effective actions for tackling the problem of AMR. The Benchmark has been developed through collaboration with experts and specialists across the spectrum of organisations working to curb AMR.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved